Maxwealth CSI All Share Medical Apparatus And Instruments ETF(159883) Rises 0.63% Intraday,Industry Spatial Distribution Pattern Takes Shape

NewTimeSpace News: As of 14:38 on April 7, 2026, the CSI All-Share Medical Devices Index (H30217) gained 0.52%. Constituent stocks: Intech Medical rose 9.34%, Zhonghong Medical 8.30%, Allmed Medical 7.99%, Jimin Health 6.88%, and Blue Sail Medical 6.42%.Maxwealth CSI All Share Medical Apparatus And Instruments ETF(159883) rose 0.63% to 0.48 yuan. Over the longer term, as of April 3, 2026, the ETF had climbed 3.70% cumulatively in the past two weeks, ranking 2/4 among comparable funds. (Stocks listed above are index constituents only, no specific recommendation implied.)

In terms of liquidity,Maxwealth CSI All Share Medical Apparatus And Instruments ETFposted an intraday turnover rate of 1.5% and trading volume of 83.4305 million yuan. As of April 3, its average daily trading volume in the past week reached 157 million yuan, ranking first among comparable funds.

In terms of size, the ETF expanded by 690 million yuan in the past three months, achieving notable growth, with new scale ranking 1/4 among comparable funds. (Data source: Wind)

In terms of shares, the ETF’s share count increased by 2 million units in the past week, showing strong growth, with new shares ranking 1/4 among comparable funds. (Data source: Wind)

Data showed that leveraged capital continued to position in the ETF. Net margin purchases ofMaxwealth CSI All Share Medical Apparatus And Instruments ETFreached 2.888 million yuan on the previous trading day, with the latest margin balance standing at 236 million yuan. (Data source: Wind)

In terms of profitability, as of April 3, 2026, since inception, the ETF recorded a maximum single-month return of 22.97%, a longest winning streak of 4 months with a cumulative gain of 19.79%, and an average return of 4.57% in rising months. As of April 3, 2026, the ETF had outperformed its benchmark by an annualized return of 1.05% over the past two years, ranking in the top 2/4 among comparable funds.

In terms of drawdown, as of April 3, 2026, the ETF’s relative drawdown versus its benchmark stood at 0.17% since the start of the year.

In terms of fees, the ETF charges a management fee of 0.50% and a custody fee of 0.10%, representing a relatively low fee level among comparable funds.

In terms of tracking accuracy, as of April 3, 2026, the ETF’s tracking error over the past month was 0.009%, the highest among comparable funds.

Notably, the CSI All-Share Medical Devices Index tracked by the fund is at a historically low valuation. Its latest price-to-book ratio (PB) is 2.85 times, lower than 94.38% of readings in the past year, indicating attractive valuation efficiency.

Maxwealth CSI All Share Medical Apparatus And Instruments ETFclosely tracks the CSI All-Share Medical Devices Index. To reflect the overall performance of companies across various sectors in the CSI All-Share Index and provide investors with analytical tools, the CSI All-Share Index constituents are classified into 11 Level-1 industries, 35 Level-2 industries, over 90 Level-3 industries, and over 200 Level-4 industries under the CSI Industry Classification. The CSI All-Share Sector Indices are then compiled using all securities in each respective industry as constituents.

Data showed that as of March 31, 2026, the top 10 weighted stocks of the CSI All-Share Medical Devices Index (H30217) were Mindray Medical, United Imaging Healthcare, Intech Medical, Andon Health, HTM Medical, Lepu Medical, Yuwell Medical, Snibe Diagnostic, Amic us, and Forever Med. The top 10 weighted stocks accounted for 44.02% of the index. (Stocks listed above are index constituents only, no specific recommendation implied.)

Industrial Research stated that China’s medical device industry has formed a relatively clear spatial distribution pattern. Regional distribution: the eastern region leads in agglomeration, the central region undertakes industrial transfer, and the western region accelerates development. Industrial chain division: R&D and innovation concentrate in core cities, while manufacturing spreads to regions with cost advantages.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.